Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
6 studies found for:    19339720 [PUBMED-IDS]
Show Display Options
Rank Status Study
1 Completed
Has Results
Cetuximab Combined With Irinotecan in First-line Therapy for Metastatic Colorectal Cancer (CRYSTAL)
Condition: Epidermal Growth Factor Receptor (EGFR) Expressing Metastatic Colorectal Cancer
Interventions: Drug: Cetuximab;   Drug: FOLFIRI (5-Fluorouracil, Folinic acid, Irinotecan)
2 Not yet recruiting Cetuximab Monotherapy Maintenance Treatment in mCRC
Condition: Colorectal Cancer
Interventions: Drug: Cetuximab;   Drug: mFOLFOX6;   Drug: FOLFIRI
3 Not yet recruiting Evaluation of CTCs Combined With Tumor Marker Detection of Efficacy of Chemotherapy in mCRC
Condition: Colorectal Cancer Metastatic
Intervention: Other: treated with FOLFIRI±cetuximab
4 Completed Exploration of Circulating VE-cadherin in Metastatic Colorectal Adenocarcinoma Patients Treated With Bevacizumab
Conditions: Colorectal Cancer;   Metastasis
Intervention: Biological: Bevacizumab + blood samples
5 Withdrawn Efficacy and Safety of Cetuximab in Metastatic Penile Carcinoma (PENILANE)
Condition: Squamous Cell Carcinoma of the Penis
Interventions: Drug: Cetuximab;   Drug: TIP
6 Terminated A Randomized, Placebo-controlled, Double-blind Phase II Study Evaluating if Glucophage Can Avoid Liver Injury Due to Chemotherapy Associated Steatosis
Conditions: Colorectal Cancer;   Steatohepatitis
Intervention: Drug: Metformin/Placebo

Study has passed its completion date and status has not been verified in more than two years.